Telix Pharmaceuticals Limited

TLX Healthcare Biotechnology

Telix Pharmaceuticals Limited’s revenue for fiscal 2025 (year ended December 2025) was $803.8 million, up 55.6% from fiscal 2024. Insiders bought in the last twelve months.

10.69 0.12 +1.14%
Market cap
$3.6B
P/E
—
Fwd P/E
—
Dividend yield
—
F-score
1/9
Altman Z
2.72
Beneish M
−1.57
Dividend safety
n/a

A Balance Sheet is a financial statement that provides a snapshot of a company's assets, liabilities, and shareholders' equity at a specific point in time. It follows the formula: Assets = Liabilities + Shareholders' Equity. Key components include current and non-current assets, current and long-term liabilities, and equity. The Balance Sheet helps businesses and investors evaluate financial stability, liquidity, and capital structure. It's essential for assessing the company's ability to meet its obligations and fund future operations.

Dec '25 Dec '24 Dec '23
Total current assets
330.28 570.12 154.48
Total non-current assets
833.71 370.26 115.24
Total Assets
1,163.99 940.38 269.72
Total current liabilities
231.62 205.09 109.67
Total non-current liabilities
516.99 382.35 61.11
Total liabilities
748.61 587.44 170.78
Common Equity (Total)
415.38 352.94 98.94
Shareholders Equity (Total)
415.38 352.94 98.94
Total Debt
461.56 358.62 11.20

Show all line items

In millions of $ except per-share values · columns are period end dates